Effect Research Antiventricular Remodeling of Qili Qiangxin Capsules in Treating Dilated Cardiomyopathy
10.13422/j.cnki.syfjx.20191332
- VernacularTitle: 芪苈强心胶囊治疗扩张型心肌病的抗心室重构作用
- Author:
Yang YANG
1
;
Ming-lei JIN
1
;
Ling-yan SONG
2
;
Yu-feng GUO
3
;
Chun-yan SONG
4
Author Information
1. Chengde Central Hospital, Chengde 067000, China
2. Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
3. Affiliated Hospital of Chengde Medical University, Chengde 067000, China
4. Fengning County Hospital of Traditional Chinese Medicine, Chengde 068350, China
- Publication Type:Research Article
- Keywords:
dilated cardiomyopathy;
Yang Qi deficiency and blood stasis syndrome;
Qili Qiangxin capsules;
myocardial fibrosis;
ventricular remodeling
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(13):99-104
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To discuss the effect of Qili Qiangxin capsules on cardiac function, myocardial fibrosis and ventricular remodeling of patients with dilated cardiomyopathy (DCM) and Yang Qi deficiency and blood stasis syndrome. Method:One hundred and seven patients were randomly divided into control group (53 cases) and observation group (54 cases) by random number table. Patients in control group got metoprolol succinate sustained-release tablet, 47.5 mg/time, 1 time/day, sacubitril valsartan sodium tablets, 50 mg/time, 1 time/day, hydrochlorothiazide tablets, 20 mg/time, 1 time/day, and spironolactone tablets, 20 mg/time, 1 time/day. In addition to the therapy of control group, patients in observation group were also given Qili Qiangxin capsules, 4 granules/time, 3 times/days. A course of treatment was 6 months. Before and after treatment, levels of left ventricular end-diastolic diameter (LVEDd), left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular myocardial mass (LVM) and left ventricular myocardial mass index (LVMI) were recorded by echocardiography. The classification of cardiac function was recorded by New York College of Cardiology (NYHA). Lee's heart failure and Yang Qi deficiency and blood stasis syndrome were scored. And levels of N-terminal B-type natriuretic peptide (NT-proBNP), soluble ST2 (sST2), galectin-3 (galectin-3), angiotensin-Ⅱ(Ang-Ⅱ), matrix metalloproteinase-2 (MMP-2), MMP-9, matrix metalloproteinase inhibitor-1 (TIMP-1), type I procollagen carboxy-terminal peptide (PIP) and type I collagen carboxy-terminal cross-linking peptide (CITP) were detected. Result:After treatment, levels of LVEDd, LVESD, IVST, LVPWT, LVM and LVMI were lower than those in control group (P<0.05), while LVEF was higher than that in control group (P<0.05). According to the rank sum test, NYHA cardiac function classification was lighter than that in control group (Z=2.031, P<0.05). After treatment, level of NT-proBNP was lower than that in control group (P<0.01), Lee's heart failure score and Yang Qi deficiency, blood stasis syndrome score sST2, galectin-3, PIP, CITP, MMP-2, MMP-9 and Ang-Ⅱ were lower than those in control group (P<0.01). Conclusion:In addition to the routine western medicine, Qili Qiangxin capsules can relieve clinical symptoms, degree of heart failure of DCM patients and ventricular remodeling, ameliorate heart function, regulate levels of sST2, galectin-3, MMPs and Ang-Ⅱ, inhibit myocardial fibrosis, and delay heart failure.
